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Of Cabbages And Kings: The Hetne Pathway
In the office of Professor Attallah Kappas there is a photograph of a smiling, apparently healthy young woman standing
with her parents. He keeps that picture "as a kind of talisman.
She was one of my first patients when I came to Rockefeller
16 years ago. Not long before the photograph was taken, she
had been extremely ill with a severe attack of acute intermittent porphyria, which had eluded proper diagnosis
elsewhere."
Dr. Kappas is physician-in-chief of The Rockefeller University Hospital, the clinical research arm of The Rockefeller
University. Most of the patients who come to the hospital
have, like the girl in the picture, serious chronic diseases;
some rare, like acute intermittent porphyria (AlP); some
more common, like diabetes, arteriosclerosis, or arthritis.
They come for treatment and to participate in laboratory
studies through which the hospital's researchers learn more
about the underlying biological mechanisms of their
disorders.
Dr. Kappas heads the hospital's metabolism-pharmacology
laboratory. He and his colleagues study liver diseases, particularly the biochemical and clinical problems that involve the
oxygen-binding pigment called heme. They explore the pathways by which heme is synthesized and degraded in the liver,
and the role heme plays in cellular metabolism and the bio-
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Dr. Kappas in his office and on the ward.
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Dr. Sassa

logical transformation of various chemicals. These chemicals
may be substances made in the body, such as steroid hormones-Dr. Kappas's original area of research-or those
that enter the body from the outside environment in the form
of drugs, pollutants, and food components.
Trained as an endocrinologist, Dr. Kappas hadn't expected,
before his arrival at Rockefeller, to be one day pondering the
genetics of the porphyrias and the biochemistry of heme and
cytochromes, studying the pharmacological effects of nutrition, or treating people suffering from lead poisoning. He had
wanted to learn more about estrogens and the liver. "But," he
explains, "as so often happens in research, you start with a
problem that has inherent depth and you find yourself crossing jurisdictions, so to speak, both clinically and scientifically.
You move with the problem." Of late, he has moved back to
endocrinology-by way of the heme pathway-to what he
hopes will result in a new and better treatment for postnatal
jaundice, a prevalent and sometimes disabling condition in
the newborn.

"THE MOST HONORED CALLING"
The first step that set Attallah Kappas on the road to clinical
science, which later in his medical-school years represented
for him "the most honored calling," was his parents' "deep

respect for learning." He earned a bachelor's degree at
Columbia University and the M.D., in 1950, from the University of Chicago School of Medicine, which 25 years later
conferred on him its Distinguished Service Award in Medical
Sciences. After a time spent at Sloan-Kettering Institute in
New York and the Peter Bent Brigham Hospital in Boston
practicing medicine and learning about steroid biochemistry,
he returned to the medical faculty of the University of Chicago in 1957. There he initiated a variety of investigations on
the pharmacology of steroid hormones in man.
In the mid-1960s, he began thinking about the effects on
the liver of estrogens, the female sex hormones. As he wrote
at the time: "It is well known that the liver plays a central role
in the transformation and biological inactivation of estrogens.
The possibility that, in this metabolic interaction, estrogens
might themselves act directly on the liver or alter its functional integrity in ways which might have clinical expression is
less widely recognized."
Although little was known then about the porphyric diseases, of which AlP is the most common hereditary form in
this country, there were strong indications-the prevalence
of attacks in women, its onset after puberty, and its exacerbation during menstruation and pregnancy-that hormones
were involved in its pathogenesis.
Sam Granick, a plant physiologist and biochemist who,
until his death in 1977, speht more than 30 years at The
Rockefeller University studying chlorophyll and other biological pigments, was- then beginning to work with cultured
-liver cells on problems concerning the regulation of porphyrin production.
"Dr. Granick had the methodology that I needed to investigate steroid influences on the liver," says Dr. Kappas. "So I
decided to take what I thought would be a year's sabbatical
from the University of Chicago to go to New York and work
with him." He arrived at Dr. Granick's laboratory in 1966 as a
guest investigator under a Guggenheim Fellowship.
The word porphyria derives from porphyrin, the generic
name for tetrapyrrole pigments, which include chlorophyll in
plants, and heme, perhaps the most important human pig-
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ment. A porphyrin is a four-ring-shaped structure. When it
has an atom of iron at the center, as is usual in higher organisms, a porphyrin becomes a heme, which binds oxygen.
Heme combines with the procein globin to make hemoglobin, which transports oxygen in the blood. It also combines
wich ocher proteins, for example in liver cells, to form
cytochromes that, among other funccions, catalyze che oxidative metabolism of chemical substances in the body. Wichoue
this oxidation process, many chemicals would act on body
organs ceaselessly, with toxic consequences.
The heme pathway is a complicated, multi-enzymatic
sequence. In AlP, the synthesis of heme is interrupted early
in the process when misinformation from an abnormal gene
causes a malfunction in an essential enzyme. As the name
implies, AlP is characterized by attacks that come and go. The
symptoms can include excruciating abdominal pain, neurological derangements including paralysis, and psychosis. "Mad"
King George III of England is believed by some ro have had a
form of porphyria.
As the work of Dr. Kappas and others has made clear,
attacks of AlP are triggered by factors in either the external
or internal environment. Shortly after his arrival at Rockefeller, he and Dr. Granick demonstrated conclusively thac natural steroids are among the triggers; as it turns out, not estrogens bue progesterone, another female hormone. So are
certain foods and drugs. Curiously, however, not everyone
with the miscreant gene shows clinical signs of AlP. For
example, the facher of the girl in the photograph also has the
genetic trait, bue has never had the disease. His sex may be an
influencing facror. Yec there are women who also carry the
AlP gene and are equally exposed to environmental triggers
but never fall prey to attacks. What began for Dr. Kappas as
"curiosity about an endocrinological question involving an
uncommon group of genecic disorders" led ro broader questions about heme biology.

CYTOCHROME P-450
The protein cytochrome P-450 is a central component of the

enzyme system involving che heme pathway. Some substances speed its action; some, like metals, inhibit it. Dr.
Kappas and his colleagues have been studying the effects of
many substances on the P-450 system in cissue culture, experimental animals, and both normal and sick people. The
Rockefeller Hospital is a center for the study of environmental pollutants, particularly lead, crace elements, and other
metals. Lead poisoning is a frequent and ofcen undetected
problem that can be extremely serious, especially in children
who are more prone than adulcs ro permanent damage of the
bone marrow, brain, or kidneys. According ro a recent report
from the Nacional Center for Health Statistics, four percent
of American preschoolers have excessive levels of lead in
their blood. A few years ago, Shigeru Sassa, a member of Dr.
Kappas's group, developed a fast, easy, precise, and inexpensive test for lead poisoning that is far more sensitive chan previous ones and is now in wide use. Dr. Sassa, who started at
Rockefeller as a graduate fellow with Dr. Granick, also developed an assay for che detection of AlP in the fetus. In Dr.
Kappas's view, "Dr. Sassa's enzymological assays and.innovative techniques for quantitative study of heme processes in
cells and tissues have been crucial to the work of this and
other laboratories studying heme biology."

Dr. Anderson, right, with
Assistant for Research Li-Lan
Tsai. Chick embryos are
injected with drugs to see the
effects on porphyrin and heme
synthesis in the liver.
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Dr. Kappas in front of The
Rockefeller University
Hospital.
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The P-450 system can be the site of competitive interplay
between chemicals; an important aspect of the laboratory's
work has been to help elucidate these interactions, especially
as they diminish the therapeutic efficacy or increase the
potential toxicity of medicinal drugs. Drug metabolism can be
affected by other drugs, cigarette smoke, alcohol, and ordinary foods.
"At the risk of taking the romance out of gourmet dining,"
says Dr. Kappas, "it is useful to remember that foods comprise many chemicals that significantly influence drug metabolism in the liver." Studies by members of the laboratory,
including several by Drs. Kappas and Karl E. Anderson in
association with Dr. Allan H. Conney from HoffmannlaRoche, have yielded some astonishing findings on nutritional influences. For example, certain vegetables, such as
cabbages and brussels sprouts, dramatically accelerate drug
metabolism; charcoal-broiled steak can speed it by as much as
950 percent in the intestine and liver. Corroboration has
come from research elsewhere on drug-nutrient interactions.
"I think there are important inferences to be drawn from
such observations if we are going to reduce the high incidence
of drug toxicity," Dr. Kappas says. "It seems obvious, to give
an extreme example, that a postoperative patient who has
been receiving nothing but glucose feedings intravenously for
a week is going to respond very differently to a drug than the
patient eating three solid meals a day."
The rate-limiting enzyme in heme breakdown is heme oxygenase. This enzyme activity increases markedly after birth,
resulting in an excessive production of bilirubin, the yellow
bile pigment that is a product of the breakdown of heme. The
disposal mechanism for bilirubin in the liver is not mature in
the newborn. In many infants, this incompetence has pathological consequences that can lead to brain damage or death.
Neonatal jaundice-hyberbilinibinemia- is caused by an
excess of bilirubin accumulating in the blood. Dr. Kappas and
Dr. George Drummond, a laboratory member from Scotland,
are applying what has been learned about the way heme oxygenase is regulated by inhibitory metals and metalloporphyrins to the development of a potential new treatment for
neonatal jaundice.

"All current therapies," Dr. Kappas states, "are directed at
getting rid of the bilirubin after it has been formed. Our
approach is to try to block bilirubin production before it
starts. The metalloporphyrin we're working with at present
has tin instead of iron in the ring structure and it can block
almost completely the binding of heme to heme oxygenase,
thus preventing bile pigment formation."
Although the treatment is stilI undergoing animal trials, the
Food and Drug Administration has approved initial studies in
adult humans. These studies look extremely promising and
have aroused considerable interest in pediatric circles. The
project especially pleases Dr. Kappas because it represents a
direct path from the lab to the bedside-every clinical
researcher's hope-and because it relates to endocrinology,
to the first question about hormones, gestation, and liver
function that captured his interest 20 years ago.

NO LONGER A GUEST
Dr. Kappas was appointed a professor in 1971 and physicianin-chief in 1974. In his role as hospital administrator, he has
overseen much-needed renovations of patient and laboratory
facilities, brought in new laboratory groups, and introduced a
program of postdoctoral training for a new generation of physician-scientists. Last year he was named Sherman Fairchild
Professor under a major new gift from the Sherman Fairchild
Foundation to support clinical research at the hospital.
The young woman in the photograph still has porphyria,
but her condition is now under control. She has never again
had an attack as severe as that first one. The work of
researchers like Dr. Kappas and his colleagues has helped to
assure that she and others like her will not, as AlP victims did
in the past, die from unnecessary surgery or inappropriate
drugs.
As for Dr. Kappas: "I planned to stay at Rockefeller just
long enough to work out one laboratory problem and its medical implications. I'm still here and I'm still working on
them."
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